Savolitinib and durvalumab for metastatic papillary kidney cancer
In a phase 2 clinical trial, patients with metastatic papillary [...]
One Cancer Voice petition: 80,000 demand diagnosis and treatment is top priority
Over 70 campaigners came together outside Westminster yesterday (Wednesday 22 [...]
Adjuvant nivolumab plus ipilimumab for localised kidney cancer
In this randomised phase 3 trial, the effectiveness and safety [...]
Fat loss may result in worse outcomes for patients treated with immunotherapy for metastatic kidney cancer
A recent study presented at the Annual Congress of the [...]
Results from a phase 3 study of 89Zr-DFO-girentuximab for PET/CT imaging of kidney cancer
Researchers are looking for better ways to diagnose kidney cancer. [...]
Improved health-related quality of life using a mindfulness app for kidney cancer patients
Randomised clinical trials have previously shown the benefit of mindfulness [...]
How time of day of immunotherapy infusion affects kidney cancer outcomes
Recent studies have suggested that the time of day when [...]
Benefits persist for lenvatinib plus pembrolizumab in advanced kidney cancer
Lenvatinib plus pembrolizumab has already been shown to improve survival [...]
TKI treatment breaks may not affect outcomes in kidney cancer
The results of the phase 2/3 STAR trial were published [...]
ASCO GU 20023: Cabozantinib as a second-line treatment for patients with advanced kidney cancer
At the American Society of Clinical Oncology Genitourinary Cancers Conference [...]
